EAM
TNGX icon

Eventide Asset Management’s Tango Therapeutics TNGX Stock Holding History

Eventide Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
+400,000
New +$9.89M 0.17% 144

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Eventide Asset Management's TNGX Position: Q2 2026 in Review

Eventide Asset Management opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 400,000 shares worth $12.5M. The stake represents 0.17% of the portfolio and ranks #144 among its holdings.

247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Eventide Asset Management held 400,000 shares of Tango Therapeutics worth $12.5M as of Q2 2026.
  • Tango Therapeutics was a new Eventide Asset Management position in Q2 2026.
  • Tango Therapeutics made up 0.17% of Eventide Asset Management's portfolio in Q2 2026, its #144 holding.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.